CRISPR Therapeutics AG (CRSP) Current Deferred Revenue (2016 - 2026)

CRISPR Therapeutics AG has disclosed Current Deferred Revenue across 11 years of filings, most recently posting $15.2 million for Q2 2026.

• In Q2 2026, Current Deferred Revenue rose 613.43% year-over-year to $15.2 million; the TTM figure through Jun 2026 stood at $15.2 million (up 613.43% YoY), while the FY2025 annual figure was $15.8 million, up 310.17% from the prior year.
• Current Deferred Revenue came in at $15.2 million for Q2 2026 at CRISPR Therapeutics AG, down from $15.3 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $15.8 million in Q4 2025 to a low of $1.3 million in Q3 2025.
• Average Current Deferred Revenue over 5 years is $7.5 million, with a median of $4.5 million recorded in 2024.
• Year-over-year, Current Deferred Revenue sank 71.11% in 2025 and surged 613.43% in 2026.
• Over 5 years, Current Deferred Revenue stood at $12.3 million in 2022, then changed by 0.0% to $12.3 million in 2023, then slumped by 68.74% to $3.8 million in 2024, then soared by 310.17% to $15.8 million in 2025, then dropped by 3.69% to $15.2 million in 2026.
• Per Business Quant data, the three most recent Current Deferred Revenue figures were $15.2 million in Q2 2026, $15.3 million in Q1 2026, and $15.8 million in Q4 2025.